ATE399549T1 - Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril - Google Patents

Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril

Info

Publication number
ATE399549T1
ATE399549T1 AT04712791T AT04712791T ATE399549T1 AT E399549 T1 ATE399549 T1 AT E399549T1 AT 04712791 T AT04712791 T AT 04712791T AT 04712791 T AT04712791 T AT 04712791T AT E399549 T1 ATE399549 T1 AT E399549T1
Authority
AT
Austria
Prior art keywords
mammal
disease
treatment
ljungan virus
caused
Prior art date
Application number
AT04712791T
Other languages
English (en)
Inventor
Bo Niklasson
Original Assignee
Apodemus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apodemus Ab filed Critical Apodemus Ab
Application granted granted Critical
Publication of ATE399549T1 publication Critical patent/ATE399549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04712791T 2003-02-21 2004-02-19 Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril ATE399549T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44845203P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ATE399549T1 true ATE399549T1 (de) 2008-07-15

Family

ID=32908591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712791T ATE399549T1 (de) 2003-02-21 2004-02-19 Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril

Country Status (5)

Country Link
US (2) US7442380B2 (de)
EP (1) EP1596859B1 (de)
AT (1) ATE399549T1 (de)
DE (1) DE602004014728D1 (de)
WO (1) WO2004073710A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399549T1 (de) * 2003-02-21 2008-07-15 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US20060229344A1 (en) * 2005-04-07 2006-10-12 John Ravits Method of treating amyotrophic lateral sclerosis
JP2009526063A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 医薬製剤
AR059359A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas que contienen pleconaril
EP2352479A4 (de) * 2008-11-05 2012-09-05 Stephen B Gold Verfahren und system zur kontrolle und verbesserung der verordnung und abgabe von arzneimitteln
GB0823560D0 (en) * 2008-12-24 2009-01-28 Apodemus Ab Virus
GB0901056D0 (en) * 2009-01-22 2009-03-11 Apodemus Ab Virus
EP2440251A4 (de) 2009-06-09 2013-01-16 Defyrus Inc Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
GB0913944D0 (en) * 2009-08-10 2009-09-16 Apodemus Ab Treatment of diseases caused by viral infection
SG184430A1 (en) * 2010-04-15 2012-11-29 Biota Scient Management Compound for treatment of respiratory condition or disease
EP2561879A1 (de) * 2011-08-23 2013-02-27 Protea Biopharma N.V. Makrophagenaktivierungsfaktor zur Verwendung bei der Behandlung des chronischen Ermüdungssyndroms sowie Erkrankungen und Störungen im Zusammenhang mit dem chronischen Ermüdungssyndrom
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
RU2667185C1 (ru) * 2017-06-14 2018-09-17 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения гипопластического варианта хронического эндометрита у пациенток с привычным невынашиванием беременности с использованием кавитированного раствора интерферона гамма
EP3989971A4 (de) * 2019-06-28 2023-08-09 Niklovir AB Neue antivirustherapien
CN114028453B (zh) * 2021-12-07 2023-05-30 北京中医药大学 广谱抗病毒药物、及其药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603305D0 (sv) * 1996-09-11 1996-09-11 Bo Niklasson New picornaviruses, vaccines and diagnostic kits
GB0120437D0 (en) * 2001-08-22 2001-10-17 Nya Apodemus Ab Diabetic model
WO2003091386A2 (en) * 2002-04-23 2003-11-06 Lindberg A Michael A new family of picornaviruses
ATE399549T1 (de) * 2003-02-21 2008-07-15 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril

Also Published As

Publication number Publication date
EP1596859B1 (de) 2008-07-02
DE602004014728D1 (de) 2008-08-14
US8231879B2 (en) 2012-07-31
US20060018876A1 (en) 2006-01-26
US20090004143A1 (en) 2009-01-01
US7442380B2 (en) 2008-10-28
WO2004073710A1 (en) 2004-09-02
EP1596859A1 (de) 2005-11-23

Similar Documents

Publication Publication Date Title
DE602004014728D1 (de) Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
AU2002360592A8 (en) Inhibitors of hepatitis c virus
NZ610715A (en) Antiviral compounds and methods
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
NZ631155A (en) Combination of two antivirals for treating hepatitis c
EA200601281A1 (ru) Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов
ATE387912T1 (de) Transepikutane darreichungsform zur behandlung des restless leg syndroms
ATE340579T1 (de) Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
JP2017514911A5 (de)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
WO2006044968A3 (en) Combination therapy for treating viral infections
NO20054158L (no) Kombinert anvendelse av ribavirin og interferon beta ved demyeliserende sykdommer
MY141506A (en) Virus therapeutic drug
RU2011131532A (ru) Способ лечения бессонницы
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
PT1220676E (pt) Prevencao do cancro colorrectal
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
WO2014193269A4 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties